Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19 | NEJM
CONCLUSIONS
The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir and those who received placebo.
ConclusionsThe time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir and those who received placebo.
